Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAT1 | P18440 | 5/20 | 1.00 |
| ▸ | PIM1 | P11309 | 2/20 | 0.74 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.74 |
| ▸ | GSK3B | P49841 | 2/20 | 0.73 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.70 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.69 |
| ▸ | CA2 | P00918 | 1/20 | 0.68 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.68 |
| ▸ | CRHBP | P24387 | 1/20 | 0.64 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.64 |
| ▸ | MMP3 | P08254 | 1/20 | 0.64 |
| ▸ | MMP13 | P45452 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | MYC | P01106 | 1/20 | 0.59 |
| ▸ | MAX | P61244 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7557614 | 1.00 | NAT1 (1.00) | NAT1PIM1PIM2GSK3BCISD1 | |
| SCHEMBL30250053 | 0.85 | NAT1 (0.74) | NAT1PIM1PIM2GSK3BCISD1 | |
| SCHEMBL8166386 | 0.85 | NAT1 (0.74) | NAT1PIM1PIM2GSK3BCISD1 | |
| SCHEMBL8166383 | 0.85 | NAT1 (0.74) | NAT1PIM1PIM2GSK3BCISD1 | |
| SCHEMBL2539679 | 0.85 | PIM1 (1.00) | NAT1PIM1PIM2GSK3BCISD1 | |
| SCHEMBL2539680 | 0.85 | PIM1 (1.00) | NAT1PIM1PIM2GSK3BCISD1 | |
| SCHEMBL2539676 | 0.85 | PIM1 (1.00) | NAT1PIM1PIM2GSK3BCISD1 | |
| SCHEMBL16709395 | 0.84 | NAT1 (0.71) | NAT1PIM1PIM2GSK3BCISD1 | |
| SCHEMBL8312154 | 0.84 | PIM1 (0.73) | NAT1PIM1PIM2CISD1ADAMTS5 | |
| SCHEMBL8312151 | 0.84 | PIM1 (0.73) | NAT1PIM1PIM2CISD1ADAMTS5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002062337-A1 | THIAZOLIDINEDIONES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-08-15 | — | — | WO | claimed |
| EP-2541329-A1 | CHARGE CONTROLLING AGENT AND TONER USING SAME | Hodogaya Chemical Co., Ltd. (JP) | 2013-01-02 | — | — | EP | disclosed |
| US-20120315576-A1 | CHARGE CONTROLLING AGENT AND TONER USING SAME | HODOGAYA CHEMICAL CO., LTD. (JP) | 2012-12-13 | — | — | US | disclosed |
| US-20120315576-A1 | CHARGE CONTROLLING AGENT AND TONER USING SAME | HODOGAYA CHEMICAL CO., LTD. (JP) | 2012-12-13 | — | — | US | disclosed |
| US-20090204336-A1 | PDZ-Domain Modulators | FORSCHUNGSVERBUND BERLIN E. V. (DE) | 2009-08-13 | — | — | US | disclosed |
| WO-2002062337-A1 | THIAZOLIDINEDIONES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-08-15 | — | — | WO | disclosed |
| EP-0915090-A1 | Compounds useful as hypoglycemic agents and for treating Alzheimer's disease | ELI LILLY AND COMPANY (US) | 1999-05-12 | — | — | EP | disclosed |
| US-5716975-A | NONTOXIC RHODANINE DERIVATIVES; ANTIDIABETIC AGENTS, CATHEPSIN D INHIBITORS, B-AMYLOID PROTEIN REDUCTION | ELI LILLY AND COMPANY (US) | 1998-02-10 | — | — | US | disclosed |
| US-5661168-A | ADMINISTERING RHODANINE DERIVATIVES TO CONTROL DIABETES | ELI LILLY AND COMPANY (US) | 1997-08-26 | — | — | US | disclosed |
| US-5523314-A | RHODANINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1996-06-04 | — | — | US | disclosed |
| EP-0587377-A2 | Thiazolidinone derivatives as hypoglycemic agents and for treating Alzheimer's disease | ELI LILLY AND COMPANY (US) | 1994-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090204336-A1 | PDZ-Domain Modulators | PDLIM5, DVL1, PSD | NAT1 4324/4885PIM1 1210/4885PIM2 913/4885 |
| US-20120315576-A1 | CHARGE CONTROLLING AGENT AND TONER USING SAME | NPY1R, HCRTR1, CCKAR | NAT1 1604/4885PIM1 3705/4885PIM2 4123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.